{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:07:29Z","timestamp":1784196449269,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004854","name":"St. Antonius Ziekenhuis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004854","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Isala Hospital"},{"DOI":"10.13039\/100005616","name":"Allergan Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005616","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction and Hypothesis<\/jats:title>\n                    <jats:p>A recent randomized controlled trial (RCT) demonstrated that while botulinum toxin A (BTA) significantly reduced pelvic floor muscle activity compared to placebo, it did not provide greater pain relief than placebo at 26\u00a0weeks. This study evaluates the effect of BTA combined with pelvic floor muscle therapy (PFMT) in placebo nonresponders and investigates long-term outcomes of BTA versus placebo in women with CPP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This open-label extension (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200927) and long-term follow-up study (initial responders\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918 and BTA nonresponders\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200931) was conducted in the Netherlands as part of an RCT. Placebo nonresponders received 100 units of BTA injected into the pelvic floor muscles during the open-label extension study. PFMT was provided at 4, 8, 12, and 26\u00a0weeks post-injection, with validated questionnaires completed at each time point and at 12 months follow-up. Primary outcomes were average pain score (0\u201310) and Patient Global Impression of Improvement. Secondary outcomes included quality-of-life questionnaires and pelvic floor muscle function. Data were analysed using mixed models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No serious safety concerns were observed. In placebo nonresponders, pain improved after BTA injections, with sustained improvement at 12 months. Among initial responders in the RCT, pain improvement persisted up to 12\u00a0months after both BTA and placebo treatment, with no significant difference between treatment groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings support the safety of BTA treatment for women with CPP. When effective, both BTA and placebo injections combined with PFMT were associated with sustained benefits for up to 1 year, although these exploratory findings should be interpreted with caution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00192-026-06814-1","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:36:43Z","timestamp":1784194603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Botulinum Toxin A Injection Treatment in Chronic Pelvic Pain Patients: Open-Label Extension Study and 12-Month Follow-Up After RCT"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6509-8270","authenticated-orcid":false,"given":"Melle A.","family":"Spruijt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-4760","authenticated-orcid":false,"given":"Wenche M.","family":"Klerkx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9107-4974","authenticated-orcid":false,"given":"Kim","family":"Notten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6118-5676","authenticated-orcid":false,"given":"Hugo","family":"van Eijndhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5768-7523","authenticated-orcid":false,"given":"Leonie","family":"Speksnijder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9986-763X","authenticated-orcid":false,"given":"Manon H.","family":"Kerkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-4304","authenticated-orcid":false,"given":"Kirsten B.","family":"Kluivers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"4","key":"6814_CR1","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/nau.23072","volume":"36","author":"R Doggweiler","year":"2017","unstructured":"Doggweiler R, Whitmore KE, Meijlink JM, Drake MJ, Frawley H, Nordling J, et al. A standard for terminology in chronic pelvic pain syndromes: a report from the chronic pelvic pain working group of the international continence society. Neurourol Urodyn. 2017;36(4):984\u20131008. https:\/\/doi.org\/10.1002\/nau.23072","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"6814_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0029-7844(95)00458-0","volume":"87","author":"SD Mathias","year":"1996","unstructured":"Mathias SD, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol. 1996;87(3):321\u20137. https:\/\/doi.org\/10.1016\/0029-7844(95)00458-0","journal-title":"Obstet Gynecol"},{"issue":"12","key":"6814_CR3","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1080\/09593985.2018.1472687","volume":"35","author":"P Fuentes-Marquez","year":"2019","unstructured":"Fuentes-Marquez P, Cabrera-Martos I, Valenza MC. Physiotherapy interventions for patients with chronic pelvic pain: a systematic review of the literature. Physiother Theory Pract. 2019;35(12):1131\u20138. https:\/\/doi.org\/10.1080\/09593985.2018.1472687","journal-title":"Physiother Theory Pract"},{"issue":"3","key":"6814_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/1471-0528.17991","volume":"132","author":"MA Spruijt","year":"2025","unstructured":"Spruijt MA, Klerkx WM, Notten K, van Eijndhoven H, Speksnijder L, Kerkhof MH, et al. The efficacy of botulinum toxin A injection in pelvic floor muscles in chronic pelvic pain patients: a double-blinded randomised controlled trial. BJOG. 2025;132(3):297\u2013305. https:\/\/doi.org\/10.1111\/1471-0528.17991","journal-title":"BJOG"},{"issue":"2","key":"6814_CR5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/jcm13020316","volume":"13","author":"SR Burtic","year":"2024","unstructured":"Burtic SR, Castiglione L, Murariu M, Rosca O, Dumitru C, Neagoe O. Assessment of quality of life in patients with chronic anal fissures: a 1-year follow-up study before and after botulinum toxin (botox) injection. J Clin Med. 2024;13(2):316. https:\/\/doi.org\/10.3390\/jcm13020316","journal-title":"J Clin Med"},{"issue":"7","key":"6814_CR6","doi-asserted-by":"publisher","first-page":"e070705","DOI":"10.1136\/bmjopen-2022-070705","volume":"13","author":"M Spruijt","year":"2023","unstructured":"Spruijt M, Kerkhof M, Rombouts M, Brohet R, Klerkx W. Efficacy of botulinum toxin A injection in pelvic floor muscles in chronic pelvic pain patients: a study protocol for a multicentre randomised controlled trial. BMJ Open. 2023;13(7):e070705. https:\/\/doi.org\/10.1136\/bmjopen-2022-070705","journal-title":"BMJ Open"},{"issue":"4","key":"6814_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/nau.22311","volume":"32","author":"PJ Voorham-van der Zalm","year":"2013","unstructured":"Voorham-van der Zalm PJ, Voorham JC, van den Bos TW, Ouwerkerk TJ, Putter H, Wasser MN, et al. Reliability and differentiation of pelvic floor muscle electromyography measurements in healthy volunteers using a new device: the Multiple Array Probe Leiden (MAPLe). Neurourol Urodyn. 2013;32(4):341\u20138. https:\/\/doi.org\/10.1002\/nau.22311","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"6814_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00192-013-2263-z","volume":"25","author":"E Utomo","year":"2014","unstructured":"Utomo E, Blok BF, Steensma AB, Korfage IJ. Validation of the pelvic floor distress inventory (PFDI-20) and pelvic floor impact questionnaire (PFIQ-7) in a Dutch population. Int Urogynecol J. 2014;25(4):531\u201344. https:\/\/doi.org\/10.1007\/s00192-013-2263-z","journal-title":"Int Urogynecol J"},{"issue":"5","key":"6814_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343. https:\/\/doi.org\/10.3109\/07853890109002087","journal-title":"Ann Med"},{"issue":"1","key":"6814_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12883-018-1094-4","volume":"18","author":"H Timmerman","year":"2018","unstructured":"Timmerman H, Wolff AP, Bronkhorst EM, Wilder-Smith OHG, Schenkels MJ, van Dasselaar NT, et al. Avoiding Catch-22: validating the PainDETECT in a in a population of patients with chronic pain. BMC Neurol. 2018;18(1):91. https:\/\/doi.org\/10.1186\/s12883-018-1094-4","journal-title":"BMC Neurol"},{"issue":"9","key":"6814_CR11","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jpain.2017.05.003","volume":"18","author":"BD Darnall","year":"2017","unstructured":"Darnall BD, Sturgeon JA, Cook KF, Taub CJ, Roy A, Burns JW, et al. Development and validation of a daily pain catastrophizing scale. J Pain. 2017;18(9):1139\u201349. https:\/\/doi.org\/10.1016\/j.jpain.2017.05.003","journal-title":"J Pain"},{"issue":"2","key":"6814_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1017\/s0033291796004382","volume":"27","author":"P Spinhoven","year":"1997","unstructured":"Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. A validation study of the hospital anxiety and depression scale (HADS) in different groups of Dutch subjects. Psychol Med. 1997;27(2):363\u201370. https:\/\/doi.org\/10.1017\/s0033291796004382","journal-title":"Psychol Med"},{"issue":"1","key":"6814_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00192-018-3718-z","volume":"30","author":"H van Dongen","year":"2019","unstructured":"van Dongen H, van der Vaart H, Kluivers KB, Elzevier H, Roovers JP, Milani AL. Dutch translation and validation of the pelvic organ prolapse\/incontinence sexual questionnaire-IUGA revised (PISQ-IR). Int Urogynecol J. 2019;30(1):107\u201314. https:\/\/doi.org\/10.1007\/s00192-018-3718-z","journal-title":"Int Urogynecol J"},{"issue":"2","key":"6814_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/1471-0528.12069","volume":"120","author":"DG Tincello","year":"2013","unstructured":"Tincello DG, Owen RK, Slack MC, Abrams KR. Validation of the patient global impression scales for use in detrusor overactivity: secondary analysis of the RELAX study. BJOG. 2013;120(2):212\u20136. https:\/\/doi.org\/10.1111\/1471-0528.12069","journal-title":"BJOG"},{"issue":"5","key":"6814_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00192-009-1069-5","volume":"21","author":"S Srikrishna","year":"2010","unstructured":"Srikrishna S, Robinson D, Cardozo L. Validation of the patient global impression of improvement (PGI-I) for urogenital prolapse. Int Urogynecol J. 2010;21(5):523\u20138. https:\/\/doi.org\/10.1007\/s00192-009-1069-5","journal-title":"Int Urogynecol J"},{"issue":"1","key":"6814_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1067\/mob.2003.379","volume":"189","author":"I Yalcin","year":"2003","unstructured":"Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol. 2003;189(1):98\u2013101. https:\/\/doi.org\/10.1067\/mob.2003.379","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"6814_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ejogrb.2006.12.014","volume":"133","author":"D Sinha","year":"2007","unstructured":"Sinha D, Karri K, Arunkalaivanan AS. Applications of botulinum toxin in urogynaecology. Eur J Obstet Gynecol Reprod Biol. 2007;133(1):4\u201311. https:\/\/doi.org\/10.1016\/j.ejogrb.2006.12.014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"7","key":"6814_CR18","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/apmr.2001.24023","volume":"82","author":"TM Cummings","year":"2001","unstructured":"Cummings TM, White AR. Needling therapies in the management of myofascial trigger point pain: a systematic review. Arch Phys Med Rehabil. 2001;82(7):986\u201392. https:\/\/doi.org\/10.1053\/apmr.2001.24023","journal-title":"Arch Phys Med Rehabil"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-026-06814-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-026-06814-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-026-06814-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:36:44Z","timestamp":1784194604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-026-06814-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":18,"alternative-id":["6814"],"URL":"https:\/\/doi.org\/10.1007\/s00192-026-06814-1","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study, in combination with our RCT, was approved by the medical ethics committee of Arnhem-Nijmegen (ID: 2017\u20133130) and all local ethical committees in accordance with the Declaration of Helsinki. The study was registered at the European Union Drug Regulating Authorities Clinical Trials Database (2017\u2013001296-23).","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Melle A Spruijt: No conflict of interest.Wenche M Klerkx: Member Dutch Urogynaecology board and Member Dutch Implant registration Committee. Both unpaid.Kim Notten: PI Dutch grant PPP allowance. Patent owner (publication number WO 2021\/224332).Hugo van Eijndhoven: No conflict of interest.Leonie Speksnijder-de Jong: NPI (Dutch Institute for Postgraduate Education in Physiotherapy): Teaching activities for postgraduate physiotherapists.Avans University of Applied Sciences: Expert lecture on gynecology for physiotherapists in training. National Symposium for Pelvic Physiotherapists: Presentation on urogynecology at the national symposium.Manon H. Kerkhof: Astellas Pharma Europe Ltd.: Consultancy board with two steeringgroup meetings. Titus health Care speaker congress.Kirsten B. Kluivers: No conflict of interest.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}